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Abstract
Identifying an effective therapeutic target is pivotal in
the treatment of gastric cancer. In this study, we in-
vestigated the expression of p75 neurotrophin recep-
tor (p75NTR) in gastric cancer and the impact of its
alteration on tumor growth. p75NTR expression was
absent or significantly decreased in 212 cases of gas-
tric cancers compared with the normal gastric mucosa
(P < .05). Moreover, p75NTR expression was also lost
or significantly decreased in various human gastric
cancer cell lines. p75NTR inhibited in vitro growth
activities and caused dramatic attenuation of tumor
growth in animal models by induction of cell cycle
arrest. Upregulation of p75NTR led to downregulation
of cyclin A, cyclin D1, cyclin E, cyclin-dependent ki-
nase 2, p-Rb, and PCNA, but to upregulation of Rb and
p27 expressions. Conversely, downregulating p75NTR
with specific siRNA yielded inverse results. The res-
cue of tumor cells from cell cycle progression by a
death domain–deleted dominant-negative antagonist
of p75NTR (#p75NTR) showed that the death do-
main transduced antiproliferative activity in a ligand-
independent manner and further demonstrated the
inhibitive effect of p75NTR on growth in gastric cancer.
Therefore, we provided evidence that p75NTR was a
potential tumor suppressor and may be used as a
therapeutic target for gastric cancer.
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Introduction
To date, gastric cancer remains a major public health
problem throughout the world, particularly in Asia, although
its incidence has declined in the West in the past decades
[1]. Advances in the treatment of this disease are likely to
come from a fuller understanding of its biology and behav-
ior. The aggressive nature of gastric cancer is related to
mutations of various oncogenes and tumor-suppressor
genes [2–6]. Previous studies have indicated the role of
several tumor-suppressor genes in tumor development and
progression, including E-cadherin/CDH1, TP53, p16 [2,5,7–
10], RUNX3 [11], and, most recently, the p75 neurotrophin re-
ceptor (p75NTR) gene.
Human p75NTR, which was known as a nerve growth factor
receptor, maps to 17q21 [12]. The gene encodes a 75-kDa cell
surface receptor glycoprotein that binds with the neurotrophin
family of growth factors [13]. Significantly, p75NTR is a mem-
ber of the tumor necrosis factor receptor superfamily [14],
which exerts diverse functions during neuronal development,
the mechanisms of which have remained elusive [15]. It has
been shown to mediate cell death and proliferation in many
different cell types, depending on the environment of the cell
[16]. It is now apparent that p75NTR is widely expressed in
many kinds of organs, tissues, and human cancers, such as
breast cancer [17], acute leukemia [18], papillary thyroid car-
cinoma [19], human pancreatic cancer [20] and prostate carci-
noma [21], and is not limited to the nervous system [13]. Recent
studies have shown that p75NTR has been identified as a
potential tumor suppressor in prostate cancer [22]. In addition,
it has been identified as a survival receptor in brain-metastatic
melanoma cells [23]. Thus, it is difficult to analyze the function
of p75NTR because the main physiological role of p75NTR
changes dramatically depending on cell context. The aim of
the present study was to know: 1) whether p75NTR is pres-
ent in gastric cancer; 2) whether its presence is related to
the malignant phenotype and growth of gastric cancer; and
3) the possible role of p75NTR, which is involved in the
growth of gastric cancer. In the present study, we found that
p75NTR could regulate cell cycle effectors of gastric cancer.
Induction of cell cycle arrest was, at least in part, responsible
for the antitumor activity of p75NTR in gastric cancer. Our data
indicated that p75NTR was a potential tumor suppressor of
gastric cancer and may be used as a therapeutic target for
gastric cancer.
Address all correspondence to: Daiming Fan, State Key Laboratory of Cancer Biology and
Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, 17
Changle Western Road, Xi’an, Shaanxi Province 710032, China. E-mail: fandaim@fmmu.edu.cn
1Haifeng Jin, Yanglin Pan, and Lina Zhao contributed equally to this work.
Received 6 February 2007; Revised 6 February 2007; Accepted 21 March 2007.
Copyright D 2007 Neoplasia Press, Inc. All rights reserved 1522-8002/07/$25.00
DOI 10.1593/neo.07175





Immunohistochemistry was performed as previously de-
scribed [24]. Tissue samples from 212 gastric cancers
and 106 normal gastric mucosae were obtained from pa-
tients who underwent surgery at the Department of General
Surgery in Xijing Hospital (Xi’an, China). All patients who
agreed to have their surgical tissues dissected for the study
signed an informed consent. All cases of gastric cancer
had been clinically and pathologically proven (data not
shown). The protocols used in the study were approved by
the hospital’s Protection of Human Subjects Committee. Four-
micrometer sections of formalin-fixed paraffin-embedded
specimens were made. Slides were dewaxed, rehydrated,
incubated in 10% normal goat serum and 0.3% Triton X-100
in phosphate-buffered saline (PBS) for 1 hour, and then in-
cubated with monoclonal anti-p75NTR antibody (1:100;
Sigma, Swampscott, MA). The slides were washed in PBS
thrice for 5 minutes each. The tissues were incubated in
biotin-labeled rabbit anti-mouse serum (1:200) for 30 min-
utes, rinsed with PBS, and incubated with avidin–biotin–
peroxidase complex for 1 hour. The signal was detected
using 3,3-diaminobenzidine as chromogen. Negative control
slides using anti-6His as the primary antibody were included
in all assays. A positive reaction was indicated by a reddish
brown precipitate in the nucleus and cytoplasm. All sec-
tions were examined independently by two investigators.
Two independent investigators scored the sections without
the knowledge of patient outcome (double-blinded). An aver-
age value of two independent scores was presented in the
present study.
Expression of p75NTR was evaluated according to the
ratio of positive cells per specimen and staining intensity,
as described previously [24]. The ratio of positive cells per
specimen was evaluated quantitatively and scored as fol-
lows: 0 = staining of V 1%; 1 = staining of 2% to 25%; 2 =
staining of 26% to 50%; 3 = staining of 51% to 75%; and 4 =
staining of > 75% of the cells examined. Intensity was graded
as follows: 0 = no signal; 1 = weak; 2 = moderate; and 3 =
strong. A total score of 0 to 12 was finally calculated and
graded as negative (; score: 0–1), weak (+; score: 2–4),
moderate (++; score: 5–8), and strong (+++; score: 9–12).
Cell Culture
Human SV40-transformed immortal gastric epithelial cell
GES-1 and gastric cancer cell lines SGC7901, AGS, MKN45,
MKN28, KATOIII, and XGC9811-L [25], as described pre-
viously [26], were maintained on cell plates at 37jC and
5% CO2 in Dulbecco’s modified Eagle’s medium (Gibco
RL, Grand Island, NY) supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin.
Plasmid Construction and Cell Transfection
pSilencer3.1 (Ambion, Austin, TX) was used for the con-
struction of human p75NTRsiRNA vectors p75NTRsi1 and
p75NTRsi2, according to the manufacturer’s protocol. Two
pairs of specific oligonucleotides (P1: 5V-GAT CCG CAG
CTG CAA GCA GAA CAA GTT CAA GAG ACT TGT TCT
GCT TGC AGC TGT TTT TTG GAA A-3V, P2V: 5V-AGC TTT
TCC AAA AAA CAG CTG CAA GCA GAA CAA GTC TCT
TGA ACT TGT TCT GCT TGC AGC TGC G-3V; P2: 5V-GAT
CCG CAA GAC CTC ATA GCC AGC ATT CAA GAG ATG
CTG GCT ATG AGG TCT TGT TTT TTG GAA A-3V, P1V:
5V-AGC TTT TCC AAA AAA CAA GAC CTC ATA GCC
AGC ATC TCT TGA ATG CTG GCT ATG AGG TCT TGC
G-3V) were annealed and then subcloned into the BamHI/
HindIII cloning site of pSilencer3.1, respectively. The full-
length human p75NTR vector (pcDNA3.1-p75NTR) and the
dominant-negative antagonist Dp75NTR were gifts of Pro-
fessor Barbara Hempstead (Weill Medical College of Cornell
University) and Moses V. Chao (New York University School
of Medicine), respectively. Cell transfection was performed
with Lipofectamine2000 (Invitrogen, Carlsbad, CA), as de-
scribed in the manufacturer’s protocol. Briefly, cells were
plated and grown to 70% to 90% confluence without anti-
biotics and then transfected with 1-mg plasmids. For stable
transfection, G418 (400 mg/ml) was added into cells after
24 hours of transfection. Stably transfected cells were tran-
siently transfected with the truncated p75NTR intracellular
domain–deleted (pcDNA3.1-Dp75NTR) DNA. For transient
transfection, cells were harvested for further experiments
after 48 hours of transfection. Mixed clones were screened
and expanded for an additional 6 weeks. The gastric cancer
cell lines SGC7901 and MKN45 transfected with pcDNA3.1-
V5/6His-p75NTR B, p75NTRsi1, p75NTRsi2, pSilencer, and
pcDNA3.1-V5/6His B were designated as SGC7901 (or
MKN45) p75NTR, SGC7901 (or MKN45) p75NTRsi1,
SGC7901 (or MKN45) p75NTRsi2, SGC7901 (or MKN45)
pSilencer, and SGC7901 (or MKN45) pcDNA, respectively.
Monolayer Growth Rate
The monolayer culture growth rate was determined,
as described previously [27], by the conversion of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Sigma Chemical Co., St. Louis, MO) into water-insoluble
formazan by viable cells. Three thousand cells in 200 ml of
medium were plated in 96-well plates and grown under
normal conditions. Cultures were assayed at 0, 1, 2, 3, 4,
and 5 days, and absorbance values were determined with as
enzyme-linked immunosorbent assay reader (DASIT, Milan,
Italy) at 490 nm. Growth curves from SGC7901 (andMKN45)
pSilencer and SGC7901 (and MKN45) pcDNA cells were
generated in parallel for comparison. Each experiment was
performed in triplicate.
Soft Agar Clonogenic Assay
Soft agar clonogenic assay was determined as described
previously [28]. Anchorage-independent growth as a char-
acteristic of in vitro tumorigenicity was assessed by soft agar
clonogenic assay. Briefly, cells were detached and plated in
0.3% agarose with a 0.5% agarose underlay (1  104 cells/
well in six-well plates). The number of foci (> 100 mm) was
counted after 17 days. Each experiment was performed
in triplicate.
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Tumorigenicity in Nude Mice
Tumorigenicity in nude mice was determined as de-
scribed previously [28]. For tumorigenicity assays, four
groups of five mice each were subcutaneously injected with
stably transfected cells at a single site. Tumor onset was
scored visually and by palpitation at the sight of injection by
two trained laboratory staff at different times on the same
day. Average tumor size was estimated by physical mea-
surement of the excised tumor at the time of sacrifice. With
the exception of mice with large tumor burdens, animals
were sacrificed 4 weeks after injection. These tumors were
verified by hematoxylin and eosin (H&E) staining. Blocks
were available for further analysis.
Cell Cycle Analysis
Flow cytometry analysis was performed as described
[29]. Cells were seeded overnight on 60-mm-diameter plates
in a complete medium, placed in a serum-free medium for
48 hours to synchronize the cells, and then kept again in the
complete medium. At 24 hours, cells were recovered. After
washing with ice-cold PBS, cells were suspended in about
0.5 ml of 70% alcohol and kept at 4jC for 30 minutes. The
suspension was filtered through a 50-mm nylon mesh, and
the DNA content of stained nuclei was analyzed by a flow
cytometer (EPICS XL; Coulter, Miami FL). Cell cycle was
analyzed using Multicycle-DNA Cell Cycle Analyzed Soft-
ware (FACScan, Becton Dickinson, San Jose, CA). The
proliferous index (PI) was calculated as: PI = (S + G2)/(S +
G2 + G1). Each experiment was performed in triplicate.
Western Blot Analysis
Protein extraction and immunoblot analyses were per-
formed as described [30]. Cells were washed twice with
Hanks balanced salt solution and lysed directly in RIPA
buffer (50 mM Tris–HCl pH 7.4, 1% vol/vol Triton X-100,
1 mM EDTA, 1 mM leupeptin, 1 mM phenylmethylsulfonyl
fluoride, 10 mM NaF, and 1 mM Na3VO4). Lysates were
centrifuged at 14,000 rpm for 30 minutes at 4jC, and super-
natants were collected. Cell lysate (60 mg) was separated
by sodium dodecyl sulfate–polyacrylamide gel electropho-
resis, blotted onto a nitrocellulose membrane, and incubated
with a primary antibody, including monoclonal antibodies
against p75NTR (diluted 1:200; Sigma Chemical Co.); cy-
clin A, cyclin D1, cyclin E, PCNA, cyclin-dependent ki-
nase (cdk) 2, and p27 (diluted 1:500; BD Biosciences, San
Jose, CA); and Rb and phosphorylated Rb (diluted 1:500;
Cell Signaling Technology, Beverly, MA). b-Actin was used
as a loading control in all Western blot analyses (diluted
1:5000; Sigma Chemical Co.). After repeated washing, the
membranes were incubated with horseradish peroxidase–
conjugated anti-mouse secondary antibody (diluted 1:2000;
Santa Cruz Biotechnology, Santa Cruz, CA). The bands
were visualized using the enhanced chemiluminescence
system (Amersham-Pharmacia Biotech, Beijing, China). Each
experiment was performed in triplicate. All examined gene ex-
pression levels were quantitatively analyzed and expressed
as ratios to b-actin.
Statistical Analysis
Statistical analysis was performed with Kruskal-Wallis
rank test, and Mann-Whitney U test was used to calculate
P values and to compare the differences between groups
for immunohistochemistry. Assays for characterizing cell
phenotype were analyzed by Student’s t test. Statistical
SPSS software package (SPSS, Inc., Chicago, IL) was used
to analyze data. Differences were considered statistically
different at P < .05.
Results
p75NTR Expression Was Decreased or Absent
in Gastric Cancer
p75NTR expression was evaluated in the 106 normal
mucosa and primary tumor tissues of all 212 patients by
immunohistochemistry. It was found that p75NTR was pre-
dominantly located in the cytoplasm and membrane of gastric
cancer cells (Figure 1). p75NTR+ expression was found in
normal gastric mucosae (88.53%) at a value higher than
that in tumor tissues of gastric cancer (40.57%) (P < .05).
When considering staining scores, the average staining
score in normal gastric mucosae was significantly higher than
that in gastric cancer (7.82 ± 2.14 vs 3.24 ± 1.53; P < .01)
(Figure 2A). As shown in Table 1, in gastric cancer specimens,
the expression of p75NTR protein in well-differentiated tumor
tissues was higher than that in moderately or poorly differen-
tiated ones (P < .01, respectively), indicating a correlation
between p75NTR expression and the differentiation grade of
gastric cancer. In addition, p75NTR expression in patients
with lymph node and/or distant metastasis (Tumor–Node–
Metastasis stages III and IV) was significantly lower than
that in patients without metastasis (Tumor–Node–Metastasis
stages I and II; P < .01), indicating a relationship between
p75NTR expression and gastric cancer metastasis. To further
confirm these observations, Western blot analysis was per-
formed using four paired human normal gastric and tumor
tissue specimens. It was clear that the tumor tissue speci-
mens had a loss or a drastic decrease in p75NTR expres-
sion compared with normal gastric tissues (Figure 2B), which
was consistent with the level of p75NTR protein expression
determined by immunohistochemical staining. After that, we
compared p75NTR expression in six gastric cancer cell lines
(SGC7901, AGS,MKN45, MKN28, KATOIII, and XGC9811-L)
[25] and one immortal gastric epithelial cell line. As shown in
Figure 2C, p75NTR expression was higher in the immortal
gastric epithelial cell line (GES-1) than in all gastric cancer
cell lines.
p75NTR Inhibits In Vitro Proliferation and Growth and
In Vivo Tumorigenicity of Gastric Cancer Cells
To downregulate the expression of p75NTR in gastric
cancer cells, two p75NTR-specific siRNA vectors, namely,
p75NTRsi1 and p75NTRsi2, were designed and con-
structed, aiming at 661 to 679 and 828 to 846 in the coding
sequence of p75NTR, respectively. After cell transfection
and antibiotic screening for 6 weeks, the expression of
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p75NTR in stably transfected cells was determined by West-
ern blot analysis. p75NTRsi1 could downregulate the ex-
pression of p75NTR in SGC7901 and MKN45 effectively,
whereas the effect of p75NTRsi2 on p75NTR expression was
minimal (Figure 3A). Then the stably transfected SGC7901-
p75NTRsi1 and MKN45-p75NTRsi1 were chosen for further
cellular assay. pcDNA-p75NTR could upregulate the expres-
sions of p75NTR in SGC7901 and MKN45. The expressions
of p75NTR were similar in SGC7901 and MKN45 cells trans-
fected with empty vectors.
When the growth curves of these cell lines were com-
pared in a medium containing 10% fetal calf serum, the
curves for p75NTRsi1 cells were significantly higher than
those for control cells, whereas the curves for p75NTR cells
were significantly lower than those for control cells (P <
.05 on days 4–7; Figure 3B). To determine the effect of
p75NTR on the colony-forming ability of gastric cancer cells,
we performed in vitro soft agar assay. The results showed
that upregulating p75NTR could decrease cell growth in
soft agar (P < .05), whereas downregulating p75NTR with
siRNA could increase cell growth (Figure 3C ). Furthermore,
in vivo subcutaneous tumor formative assay was adopted
to examine the proliferative ability of SGC7901 (and MKN45)
p75NTR in nude mice. Compared with control cells trans-
fected with empty vector, the injection of SGC7901 (and
MKN45) p75NTR cells led to a significantly decreased tumor
size. Conversely, inoculation of SGC7901 (and MKN45)
p75NTRsi1 cells led to a significantly increased tumor size
(P < .05; Figure 3D). Both in vitro and in vivo assays sug-
gested that p75NTR had the potential to inhibit the prolifer-
ation, growth, and tumorigenicity of gastric cancer.
Figure 1. Immunohistochemical staining of p75NTR in normal gastric tissues and in gastric cancer at different stages of differentiation. Monoclonal mouse anti-
p75NTR antibodies were used to stain paraffin sections. (A) A normal epithelium exhibiting positive p75NTR immunostaining. (B and C) Well-differentiated,
(D) moderately differentiated, and (E) poorly differentiated gastric cancer tissues showing moderate or weak p75NTR immunosignals in most epithelial cells.
(F) Negative control slides using anti-6His as the primary antibody. Original magnification, 20.
Figure 2. Staining score of the immunostaining of p75NTR in normal gastric
mucosa and in gastric cancer, and its expression in normal gastric (N) and
gastric tumor tissue (T) specimens and in gastric cancer cell lines. (A) The
results of immunohistochemical staining were evaluated by staining scores
described in the Materials and Methods section. *P < .05 vs normal gastric
mucosa. (B) Expression of p75NTR in normal gastric (N) and gastric tumor
tissue (T) specimens. (C) Expression of p75NTR in gastric cancer cell lines.
-Actin was used as an internal control. Representative experiment of three,
with similar results.
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Table 1. Clinicopathological Associations of p75NTR Expression in Patients with Gastric Cancer.
Total Number of Cases p75NTR Immunostaining
 + ++ +++
Normal gastric mucosa [n (%)] 106 12 (11.32) 7 (6.6) 24 (22.64) 63 (59.43)
Gastric carcinoma [n (%)] 212 128 (60.38) 30 (14.15) 42 (19.81) 12 (5.66)
Differentiation
Well differentiated 37 9 6 12 10
Moderately differentiated 91 39 13 35 4
Poorly differentiated 84 57 21 6 0
Gross type (Borrmann)
I (polypodi) 28 6 3 13 6
II (ulcerofungating) 39 7 13 14 5
III (ulceroinfiltrative) 113 5 32 50 26
IV (diffuse) 32 7 8 10 7
Tumor–Node–Metastasis
I + II 66 7 19 28 12
III + IV 146 18 36 60 32
Metastasis
With 106 84 14 6 2
Without 106 38 21 37 10
The interpretation of p75NTR staining is described in the Materials and Methods section. p75NTR staining was graded as negative (; score: 0–1), weak (+; score:
2–4), moderate (++; score: 5–8), and strong (+++; score: 9–12).
Figure 3. Effects of p75NTR and p75NTRsiRNA on the in vitro proliferation and growth and in vivo tumorigenicity of gastric cancer cells. Representative
experiment of three, with similar results. (A) After stable transfection, the expression of p75NTR was evaluated by Western blot analysis. -Actin was used as an
internal control. (B) The role of p75NTR and p75NTRsi1 in regulating the proliferation of SGC7901 and MKN45 cells. The monolayer growth rates of cells were
determined by MTT assays. Values represent the mean (standard error of the mean) from at least three separate experiments. *P < .05. (C) Effect of p75NTR and
p75NTRsi1 on the colony formation of SGC7901 and MKN45 cells. Cells were placed in media containing soft agar and incubated for 17 days. The number of
foci (> 100 m) was counted. Values represent the mean (standard error of the mean) from at least three separate experiments, each conducted in triplicate. **P =
.000. *P < .01. (D) Effect of p75NTR and p75NTRsi1 on the tumorigenicity of SGC7901 and MKN45 cells in nude mice. Average tumor size was estimated by
physical measurement of the excised tumor at the time of sacrifice. These tumors were verified as gastric cancer by H&E staining. *P < .01.
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p75NTR Induces the Cell Cycle Arrest of Gastric
Cancer Cells
To further investigate the mechanism by which p75NTR
inhibits gastric cancer cell growth, we studied the effects
of p75NTR expression on the cell cycle by fluorescence-
activated cell sorter analysis. The results of the cell cycle
showed that at 24 hours after the release of synchronized
cultures, 8.42% of SGC7901-p75NTR cells were in S-phase
compared to 12.49% of SGC7901 cells, whereas 16.53% of
SGC7901-p75NTRsi1 cells were in S-phase compared to
12.49% of SGC7901 cells (P < .05). The results were similar
in MKN45-transfected cells. Furthermore, we used a deletion
construct of p75NTR that lacks the intracellular domain
(Dp75NTR) and functions as a dominant-negative antago-
nist of p75NTR [31,32], which had been demonstrated to
have the same function in prostate cancer. We found that
Dp75NTR could reverse the effect of p75NTR on the cell
cycle by flow cytometry (Table 2). To further investigate the
mechanism by which p75NTR induced cell cycle arrest in
gastric cancer cells, we examined cell cycle effectors by
Western blot analysis. Our results indicated that upregula-
tion of p75NTR protein was associated with a reduction in
cyclin A, cyclin D1, cyclin E, cdk2, p-Rb, and PCNA pro-
teins, but with an increase in p27 and Rb proteins. However,
downregulation of p75NTR protein by siRNA correlated with
the increase in cyclin A, cyclin D1, cyclin E, cdk2, p-Rb, and
PCNA proteins, but with reduction in p27 and Rb proteins.
To further confirm the role of p75NTR in regulating cell cy-
cle effectors, we used Dp75NTR, which functions as the
dominant-negative antagonist of p75NTR. Transfection of
Dp75NTR appeared to rescue the p75NTR-associated de-
crease in cyclin A, cyclin D1, cyclin E, cdk2, p-Rb, and
PCNA, and to suppress the expression of p27 and Rb (Fig-
ure 4). The levels of b-actin loading control between samples
appeared similar.
Discussion
During the carcinogenesis of stomach cancer, various ge-
netic and epigenetic alterations accumulate to facilitate cell
transformation and to enhance aggressive behaviors. Al-
though a number of cellular genes have been identified to
be involved in gastric carcinogenesis, the tumorigenesis
and progression of gastric cancer have not been fully eluci-
dated. Therefore, it is vital to identify more proteins specifi-
cally related to gastric carcinogenesis, which may expand
our understanding of this disease and may develop new tar-
gets for therapy and indicators for diagnosis.
p75NTR gene is a member of the tumor necrosis factor
receptor superfamily [14], which was found to be expressed
in many kinds of organs, tissues, and human cancers. Its
exact role in carcinomas is not fully elucidated. Above all, its
expression in gastric cancer, the effect of its alterations on
the growth of gastric cancer, and the use of this pathway for
targeted cancer therapy have remained unelucidated. In the
present study, we provided evidence that p75NTR was a
tumor suppressor of gastric cancer. Specifically, we found
that p75NTR protein was expressed in the membrane and
cytoplasm of epithelial cells of gastric mucosa, whereas there
was a significant decrease or absence of p75NTR expression
in gastric cancer specimens at a high frequency. In addition,
we found that p75NTR+ expression in normal gastric mucosae
was higher than that in tumor tissues of gastric cancer; the
average staining score in normal gastric mucosae was signifi-
cantly higher than that in gastric cancer. It suggested that
p75NTR could play roles in gastric carcinogenesis and may
have an inhibitory effect on the proliferation of gastric cancer
cells. In this report, p75NTR expression was found to be
downregulated in gastric cancer cell lines compared with the
normal gastric epithelial cell line by Western blot analysis.
Our work confirmed and extended previous observations that
p75NTR is downregulated in gastric cancer.
To determine whether the ectopic expression of p75NTR
could modulate the proliferation of gastric cancer cells, we
introduced pcDNA-p75NTR and pSilencer-p75NTRsi1 into
SGC7901 and MKN45 cells, respectively. As a result, we
found that p75NTR significantly inhibited gastric cancer cell
proliferation and growth in vitro and tumorigenicity in animal
models. The stimulatory effects of pSilencer-p75NTRsi1 and
the suppressive effect of pcDNA-p75NTR on SGC7901 and
MKN45 cells showed that p75NTR gene may be a growth
arrest gene that acts directly or indirectly to control the pro-
liferation of cells. The products of such genes regulate cell
growth and differentiation in a negative fashion, thus sup-
pressing neoplastic development, which further indicated
that p75NTR could act as a tumor suppressor in gastric can-
cer. Then we demonstrated that a component of p75NTR
tumor-suppressor activity is mediated by the inhibition of cell
Table 2. Cell Cycle Analysis of p75NTR Expression in SGC7901 and MKN45 Cells.
SGC7901 (MKN45) Clones Expressing the p75NTR Protein (A) Mock (B) Dp75NTR
G1 G2 S G1 G2 S
p75NTR 80.34 (82.13) 11.24 (10.37) 8.42 (7.5) 58.29 (61.75) 22.74 (21.36) 19.97 (16.89)
pcDNA 75.17 (74.25) 11.89 (11.86) 12.94 (13.89) 63.43 (64.37) 20.79 (22.12) 15.78 (13.51)
Cont 75.78 (74.15) 11.73 (10.78) 12.49 (15.07) 64.51 (65.48) 21.38 (21.62) 14.11 (12.9)
pSilencer 76.06 (74.95) 12.03 (11.14) 11.91 (13.91) 63.54 (65.17) 21.49 (21.91) 14.97 (12.92)
p75NTRsi1 71.89 (68.54) 11.58 (12.06) 16.53 (19.4) 69.83 (70.23) 19.74 (22.15) 10.43 (7.62)
Statistical significance * NS * * NS *
Enumeration (%) of cell cycle analysis in SGC7901(MKN45) clones. (A) Mock cells. (B) Death domain–deleted p75NTR-transfected cells.
NS, not significant.
*P < .05 (representative experiment of three, with similar results).
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cycle progression commensurate with increased accumula-
tion of cancer cells in G1-phase and a corresponding reduc-
tion of cells in the S-phase of the cell cycle in the SGC7901
and MKN45 gastric cancer cell lines. Significantly, the res-
cue of tumor cells from retarded cell cycle progression by
a death domain–deleted dominant-negative antagonist of
p75NTR shows that the death domain transduced antipro-
liferative activity in a ligand-independent manner. The inter-
action of the truncated p75NTR lacking the death domain
with full-length p75NTR antagonizes wild-type p75NTR pro-
tein function [32].
It is well known that cell cycle initiation and progression
are regulated by several classic cdks. The expression of
cyclin D complexed with PCNA has been shown to promote
the phosphorylation of Rb during progression from early to
mid-G1 [33]. Beyond mid-G1, near the end of the G1/S re-
striction point, the expression of cyclin E complexed with
cdk2 has been shown to promote the phosphorylation of
Rb [34,35]. Beyond the G1/S restriction point, expression of
the cyclin A/cdk2 complex has been shown to maintain the
phosphorylation of Rb during the S-phase of the cell cycle
[36,37]. Inversely, p27 belongs to the Cip/Kip family, which
acts as a broad specific inhibitor of cyclin D, cyclin E, and
cyclin A complexes. The deregulation of these CDKIs is a
common feature in tumor cells and mainly contributes to the
disruption of cell cycle control. p27Kip1 (p27) is a CDKI that
exerts its inhibitory activity on many steps of the cell cycle
[38]. Clearly in our studies, p75NTR downregulated cyclin
D1, PCNA, and phosphorylated Rb proteins, which indicates
that p75NTR was associated with retarded progression
through early to mid-G1. In addition, the p75NTR down-
regulation of cyclin E and cdk2 proteins in gastric cancer
cells indicates that progression through the G1/S restriction
point is regulated by p75NTR protein expression. Likewise,
suppression of cdk2 and cyclin A supports the selective
effect of p75NTR expression on retarding progression
through the S-phase of the cell cycle, although p75NTR
upregulation of p27 protein further indicated its inhibition of
the cell cycle in gastric cancer. The rescue of cyclin D1,
PCNA, and phosphorylated Rb levels by the death domain–
deleted dominant-negative antagonist of p75NTR shows
a p75NTR-dependent regulation of the cell cycle in gastric
cells. Taken together, it seems clear that p75NTR expression
selectively alters specific cell cycle–regulatory molecules
that retard progression from early to mid-G1, the G1/S restric-
tion point, and the S-phase of the cell cycle in gastric cancer.
In conclusion, p75NTR could be an effective gene thera-
peutic target for gastric cancer. As shown in this research,
enforced p75NTR expression significantly inhibited gastric
cancer growth in vitro and in vivo by induced accumulation
and concomitant reduction of cells in the G1 and S phases,
respectively, of the cell cycle. Further research may help de-
sign an effective therapeutic modality to control gastric cancer.
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